Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mitoxantrone in malignant lymphoma.

R A Gams, S Bryan, G Dukart

    Investigational New Drugs
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Drug induced aseptic meningitis due to diclofenac.

    Journal of neurology·2003
    Same author

    Differential activity of the gelatinases (matrix metalloproteinases 2 and 9) in the fetal membranes and decidua, associated with labour.

    Molecular human reproduction·2003
    Same author

    A comparison of total intravenous with balanced anaesthesia for middle ear surgery: effects on postoperative nausea and vomiting, pain, and conditions of surgery.

    Anaesthesia·2003
    Same author

    Pseudomembranous tracheobronchial aspergillosis: a rare manifestation of invasive aspergillosis in a non-neutropenic patient with Hodgkin's disease.

    Mycoses·2003
    Same author

    [Acute lymphatic leukemia in the adult. Diagnosis, risk groups and therapy].

    Der Internist·2003
    Same author

    [Echocardiographic detection of tricuspid valve endocarditis and right atrial and ventricular masses in a patient with acute myeloid leukaemia].

    Ultraschall in der Medizin (Stuttgart, Germany : 1980)·2002

    Mitoxantrone shows activity in refractory malignant lymphoma. A dose of 14 mg/m2 every three weeks yielded a higher response rate with minimal side effects compared to weekly administration.

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Malignant lymphoma is a significant health concern.
    • Mitoxantrone is an anthracenedione chemotherapy agent.

    Purpose of the Study:

    • To evaluate the efficacy and safety of mitoxantrone in refractory malignant lymphoma.
    • To compare two different dosing regimens of mitoxantrone.

    Main Methods:

    • Two Phase II clinical trials were conducted.
    • Trial 1: Mitoxantrone 5 mg/m2 weekly for six weeks (SECSG).
    • Trial 2: Mitoxantrone 14 mg/m2 every three weeks (multicenter).

    Main Results:

    • Weekly regimen: 3 partial responses, no complete responses; significant myelosuppression.
    • Three-weekly regimen: 4 complete and 26 partial responses; minimal side effects.

    Related Experiment Videos

  • All responders had prior extensive therapy, including anthracyclines.

    • Conclusions:

    • Mitoxantrone demonstrates significant activity in refractory malignant lymphoma.
    • The 14 mg/m2 every three weeks dosing schedule appears more effective and tolerable.
    • Further Phase III trials should consider this optimized dose schedule.